FDA probes cognitive impact of new cholesterol drugs; Regeneron, Sanofi shares fall

(Reuters) – The U.S. Food and Drug Administration has called for an assessment of potential neurocognitive side effects of an experimental cholesterol drug being developed by Regeneron and Sanofi,…

    

Leave a Reply

Your email address will not be published.